Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin

BACKGROUND: Oral semaglutide was approved in 2019 for blood glucose control in patients with type 2 diabetes mellitus (T2DM) and was the first oral glucagon-like peptide 1 receptor agonist (GLP-1 RA). T2DM is associated with substantial healthcare expenditures in the US, so the cost of a new interve...

Descripción completa

Detalles Bibliográficos
Autores principales: Wehler, Elizabeth, Lautsch, Dominik, Kowal, Stacey, Davies, Glenn, Briggs, Andrew, Li, Qianyi, Rajpathak, Swapnil, Alsumali, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882575/
https://www.ncbi.nlm.nih.gov/pubmed/33150566
http://dx.doi.org/10.1007/s40273-020-00967-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882575/
https://www.ncbi.nlm.nih.gov/pubmed/33150566
http://dx.doi.org/10.1007/s40273-020-00967-7

Ejemplares similares